We can’t show the full text here under this license. Use the link below to read it at the source.
Is glucose‐induced hypersecretion of glicentin after the revision surgery using Roux‐en‐Y gastric bypass related to improved glycemic control due to insulin hypersecretion in a type 2 diabetes patient without diabetes remission after laparoscopic sleeve gastrectomy?
Is increased glicentin release after gastric bypass linked to better blood sugar control from higher insulin in a type 2 diabetes patient without remission after sleeve gastrectomy?
AI simplified
Abstract
A morbidly obese patient with type 2 diabetes showed improved hyperglycemia after surgery following initial failure of diabetes remission from .
- The patient experienced a significant improvement in blood sugar levels post-surgery.
- Passage failure of solid food intake at the gastric angle resolved after the revision surgery.
- Insulin and secretion increased notably after Roux-en-Y gastric bypass compared to after sleeve gastrectomy.
- Minor changes were observed in the secretion of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) during the oral glucose tolerance test after Roux-en-Y gastric bypass.
- Further research is necessary to determine if the increased glicentin secretion is related to enhanced insulin secretion.
AI simplified
Key numbers
4.7 kg
Body Weight Decrease
Weight change from 78.7 kg post- to 74 kg post-.
4.1%
Improvement
changed from 11.4% post- to 7.3% post-.
58.5 μU/mL
Insulin Level Increase
Insulin level at 30 minutes post- during .